Skip to main content
. 2015 Apr;110(2):157–165. doi: 10.1590/0074-02760140280

TABLE IV. Test properties calculated after creating a 2 x 2 table.

Reference Casesa Controlsb Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Accuracy (95% CI)
Piñero et al. (1999) 36 (30) 19 (0) 83.33 (68.11-92.13) 100 (83.18-100) 100 (88.65-100) 76.00 (56.57-88.5) 89.09 (78.17-94.9)
Pirmez et al. (1999) 30 (23) 14 (0) 76.67 (59.07-88.21) 100 (78.47-100) 100 (85.69-100) 66.67 (45.37-82.81) 84.09 (70.63-92.07)
Victoir et al. (2003) 15 (11) 5 (0) 73.33 (48.05-89.1) 100 (56.55-100) 100 (74.12-100) 55.56 (26.66-81.12) 80 (58.4-91.03)
Disch et al. (2005) 51 c 13 (11) 10 (0) 84.62 (57.76-95.67) 100 (75.25-100) 100 (74.12-100) 83.33 (55.2-95.3) 91.3 (73.2-97.58)
Disch et al. (2005) 120 c 13 (11) 10 (0) 84.62 (57.76-95.67) 100 (75.25-100) 100 (74.12-100) 83.33 (55.2-95.3) 91.3 (73.2-97.58)
Camera et al. (2006) 20 (7) 37 (9) 35 (18.12-56.71) 75.68 (59.88-86.64) 43.75 (23.1-66.82) 68.29 (53.02-80.44) 61.4 (48.43-72.94)
Bracho et al. (2007) kDNA d 35 (24) 25 (2) 68.57 (52.02-81.45) 92 (75.03-97.78) 92.31 (75.86-97.86) 67.65 (50.84-80.87) 78.33 (66.38-86.88)
Bracho et al. (2007) ITS d 35 (14) 25 (1) 40 (25.55-56.43) 96 (80.46-99.29) 93.33 (70.18-98.81) 53.33 (39.08-67.07) 63.33 (50.68-74.38)
Deborggraeve et al. (2008) 12 (11) 8 (0) 91.67 (64.61-98.51) 100 (67.56-100) 100 (74.12-100) 88.89 (56.5-98.01) 95 (76.39-99.11)
Pereira et al. (2008) 14 (12) 3 (0) 85.71 (60.06-95.99) 100 (43.85-100) 100 (75.15-100) 60 (23.07-88.24) 88.24 (65.66-96.71)
Fagundes et al. (2010) 15 (14) 15 (1) 93.33 (70.18-98.81) 93.33 (70.18-98.81) 93.33 (70.18-98.81) 93.33 (70.18-98.81) 93.33 (78.68-98.15)
Boggild et al. (2011) Cervisoft ® 23 (22) 10 (1) 95.65 (79.01-99.23) 90 (59.58-98.21) 95.65 (79.01-99.23) 90 (59.58-98.21) 93.94 (80.39-98.32)
Boggild et al. (2011) Hystobrush ® 23 (21) 10 (1) 91.3 (73.20-97.58) 90 (59.58-98.21) 95.45 (78.20-99.19) 81.82 (52.30-94.86) 90.91 (76.43-96.86)
Boggild et al. (2011) Biopsy e 23 (22) 5 (0) 95.65 (70.01-99.23) 100 (56.55-100) 100 (85.13-100) 83.33 (43.65-96.99) 96.43 (82.29-99.37)
Thomaz-Soccol et al. (2011) MP1L/MP3H f 15 (15) 6 (0) 100 (79.61-100) 100 (60.97-100) 100 (79.61-100) 100 (60.97-100) 100 (84.54-100)
Thomaz-Soccol et al. (2011) B1/B2 f 15 (15) 6 (0) 100 (79.61-100) 100 (60.97-100) 100 (79.61-100) 100 (60.97-100) 100 (84.54-100)
Veland et al. (2011) 8 (6) 32 (0) 75 (43.93-92.85) 100 (89.28-100) 100 (60.97-100) 94.12 (80.91-98.37) 95 (83.5-98.62)
Marco et al. (2012) 9 (8) 19 (3) 88.89 (56.5-98.01) 84.21 (62.43-94.48) 72.73 (43.43-90.25) 94.12 (73.02-98.95) 85.71 (68.51-94.3)
Neitzke-Abreu et al. (2013) Blood e 10 (6) 117 (2) 60 (31.27-83.18) 98.29 (93.98-99.53) 75 (40.93-92.85) 96.64 (91.68-98.69) 95.28 (90.08-97.82)
Gomes et al. (2014a) Biopsy e 13 (8) 30 (0) 61.54 (35.52-82.29) 100 (88.65-100) 100 (67.56-100) 85.71 (70.62-93.74) 88.37 (75.52-94.93)

a: true positives; b: false positives; c: amplicon size; d: polymerase chain reaction target; e: collected material; f: primers; CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value. Publications with more than one collection or amplification method were subdivided.